May 21 () - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another ‌part ...

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market ...

Eli Lilly's Mounjaro has overtaken Keytruda to become the world's top-selling medicine. Its rise highlights booming demand ...

Regeneron (REGN) stock is in focus as the firm fails in a late-stage trial testing a combination therapy involving its ...

A combo of two blockbuster breast cancer drugs was so successful in keeping an aggressive type of the disease from worsening, it is likely to change how young patients are treated, experts said after ...

Thousands of patients will be offered a new injectable form of an immunotherapy drug that takes minutes.

Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...

The Department of Health says it is "aware" of the jab and is "exploring" how it can be made available "as soon as possible".

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

AHMEDABAD, India and PLANEGG-MARTINSRIED, Germany, Dec. 9, 2025 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an ...